Dave Asprey
speaker
17,208 appearances
48 recordings
1 series
first heard May 2026
last heard 14 Aug
Dave Asprey’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 48 in all, peaking in Jul 2026 with 18.
Appearances
The folks at King's College London took keratin, the protein extracted from sheep's wool, and turned it into a scaffold material for bone regeneration.
They tested it against collagen, which has been the gold standard in bone and dental repair for decades, first on human bone cells in the lab, and then in rats with skull defects large enough that they wouldn't heal naturally.
Collagen still produced more total bone volume, but the bone grown with the keratin scaffold was more organized, more structurally sound, and closer to what natural, healthy bone actually looks like.
This distinction is one to keep in mind, because collagen is soft, it degrades fast, and it's never held up well for weight-bearing bone, which is a real limitation if you're talking about any serious repair.
Keratin held its structure during healing and integrated cleanly with the surrounding tissue, which are the two things you actually need for a scaffold to work in a real patient, not just a lab dish.
And there's a sustainable
Sustainability angle as well.
Wool is a waste byproduct of the farming industry that gets thrown out at scale, and collagen extraction is expensive and complicated by comparison.
So you've got a material that's cheaper to source, better for the planet, and produces a structurally superior result.
This is great news if you're facing any kind of bone graft, dental implant, or craniofacial repair in the
coming years.
Ask your surgeon whether keratin-based scaffolds have entered clinical trials yet, because this has real potential to replace collagen as the default.
For story four, a company called Structure Therapeutics published phase two B data on an oral GLP one pill called alinoglypron, and at the highest dose, people lost over twelve percent of their body weight in thirty-six weeks, with sixteen percent showing up in the open label extension.
That puts it in the same range as what people get from Wigovi and Ozempic, except it's a pill instead of a weekly injection.
Longevity aside, I've stayed skeptical of certain uses of injectable GLP ones because of muscle loss and rebound weight gain the moment people stop.
But I can't ignore that an oral option changes the compliance equation completely.
Needles are a real barrier for a lot of people, and a pill that doesn't plateau after thirty six weeks is worth watching closely.
My concern hasn't moved though for part of this GLP conversation.
None of these drugs address why people gain the weight in the first place, whether that's insulin resistance, mitochondrial dysfunction, or food engineered to be addictive.
A pill is easier to take, but it's still a patch on a problem that has a greater cause.
Showing 41–60 of 17,208 · page 3 of 861
← Previous
Next →